Bortezomib improves adoptive T-Cell therapy by sensitizing cancer cells to FasL cytotoxicity

Anil Shanker, Samuel T. Pellom, Duafalia F. Dudimah, Menaka Thounaojam, Rachel L. De Kluyver, Alan D. Brooks, Hideo Yagita, Daniel W. McVicar, William J. Murphy, Dan L. Longo, Thomas J. Sayers

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Cancer immunotherapy shows great promise but many patients fail to show objective responses, including in cancers that can respond well, such as melanoma and renal adenocarcinoma. The proteasome inhibitor bortezomib sensitizes solid tumors to apoptosis in response to TNF-family death ligands. Because T cells provide multiple death ligands at the tumor site, we investigated the effects of bortezomib on T-cell responses in immunotherapy models involving low-avidity antigens. Bortezomib did not affect lymphocyte or tissue-resident CD11c+ CD8+ dendritic cell counts in tumor-bearing mice, did not inhibit dendritic cell expression of costimulatory molecules, and did not decrease MHC class I/II-associated antigen presentation to cognate T cells. Rather, bortezomib activated NF-κB p65 in CD8+ T cells, stabilizing expression of T-cell receptor CD3ζ and IL2 receptor-α, while maintaining IFNγ secretion to improve FasL-mediated tumor lysis. Notably, bortezomib increased tumor cell surface expression of Fas in mice as well as human melanoma tissue from a responsive patient. In renal tumor-bearing immunodeficient Rag2-/- mice, bortezomib treatment after adoptive T-cell immunotherapy reduced lung metastases and enhanced host survival. Our findings highlight the potential of proteasome inhibitors to enhance antitumor T-cell function in the context of cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)5260-5272
Number of pages13
JournalCancer Research
Volume75
Issue number24
DOIs
StatePublished - Dec 15 2015

Fingerprint

Cell- and Tissue-Based Therapy
T-Lymphocytes
Neoplasms
Immunotherapy
Proteasome Inhibitors
Dendritic Cells
Melanoma
Ligands
Bortezomib
Interleukin-2 Receptors
Antigen Presentation
T-Cell Antigen Receptor
Renal Cell Carcinoma
Cell Count
Lymphocytes
Apoptosis
Neoplasm Metastasis
Kidney
Antigens
Lung

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Shanker, A., Pellom, S. T., Dudimah, D. F., Thounaojam, M., De Kluyver, R. L., Brooks, A. D., ... Sayers, T. J. (2015). Bortezomib improves adoptive T-Cell therapy by sensitizing cancer cells to FasL cytotoxicity. Cancer Research, 75(24), 5260-5272. https://doi.org/10.1158/0008-5472.CAN-15-0794

Bortezomib improves adoptive T-Cell therapy by sensitizing cancer cells to FasL cytotoxicity. / Shanker, Anil; Pellom, Samuel T.; Dudimah, Duafalia F.; Thounaojam, Menaka; De Kluyver, Rachel L.; Brooks, Alan D.; Yagita, Hideo; McVicar, Daniel W.; Murphy, William J.; Longo, Dan L.; Sayers, Thomas J.

In: Cancer Research, Vol. 75, No. 24, 15.12.2015, p. 5260-5272.

Research output: Contribution to journalArticle

Shanker, A, Pellom, ST, Dudimah, DF, Thounaojam, M, De Kluyver, RL, Brooks, AD, Yagita, H, McVicar, DW, Murphy, WJ, Longo, DL & Sayers, TJ 2015, 'Bortezomib improves adoptive T-Cell therapy by sensitizing cancer cells to FasL cytotoxicity', Cancer Research, vol. 75, no. 24, pp. 5260-5272. https://doi.org/10.1158/0008-5472.CAN-15-0794
Shanker, Anil ; Pellom, Samuel T. ; Dudimah, Duafalia F. ; Thounaojam, Menaka ; De Kluyver, Rachel L. ; Brooks, Alan D. ; Yagita, Hideo ; McVicar, Daniel W. ; Murphy, William J. ; Longo, Dan L. ; Sayers, Thomas J. / Bortezomib improves adoptive T-Cell therapy by sensitizing cancer cells to FasL cytotoxicity. In: Cancer Research. 2015 ; Vol. 75, No. 24. pp. 5260-5272.
@article{545ae850351a4dc7b0a7ffd557f2df69,
title = "Bortezomib improves adoptive T-Cell therapy by sensitizing cancer cells to FasL cytotoxicity",
abstract = "Cancer immunotherapy shows great promise but many patients fail to show objective responses, including in cancers that can respond well, such as melanoma and renal adenocarcinoma. The proteasome inhibitor bortezomib sensitizes solid tumors to apoptosis in response to TNF-family death ligands. Because T cells provide multiple death ligands at the tumor site, we investigated the effects of bortezomib on T-cell responses in immunotherapy models involving low-avidity antigens. Bortezomib did not affect lymphocyte or tissue-resident CD11c+ CD8+ dendritic cell counts in tumor-bearing mice, did not inhibit dendritic cell expression of costimulatory molecules, and did not decrease MHC class I/II-associated antigen presentation to cognate T cells. Rather, bortezomib activated NF-κB p65 in CD8+ T cells, stabilizing expression of T-cell receptor CD3ζ and IL2 receptor-α, while maintaining IFNγ secretion to improve FasL-mediated tumor lysis. Notably, bortezomib increased tumor cell surface expression of Fas in mice as well as human melanoma tissue from a responsive patient. In renal tumor-bearing immunodeficient Rag2-/- mice, bortezomib treatment after adoptive T-cell immunotherapy reduced lung metastases and enhanced host survival. Our findings highlight the potential of proteasome inhibitors to enhance antitumor T-cell function in the context of cancer immunotherapy.",
author = "Anil Shanker and Pellom, {Samuel T.} and Dudimah, {Duafalia F.} and Menaka Thounaojam and {De Kluyver}, {Rachel L.} and Brooks, {Alan D.} and Hideo Yagita and McVicar, {Daniel W.} and Murphy, {William J.} and Longo, {Dan L.} and Sayers, {Thomas J.}",
year = "2015",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-15-0794",
language = "English (US)",
volume = "75",
pages = "5260--5272",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Bortezomib improves adoptive T-Cell therapy by sensitizing cancer cells to FasL cytotoxicity

AU - Shanker, Anil

AU - Pellom, Samuel T.

AU - Dudimah, Duafalia F.

AU - Thounaojam, Menaka

AU - De Kluyver, Rachel L.

AU - Brooks, Alan D.

AU - Yagita, Hideo

AU - McVicar, Daniel W.

AU - Murphy, William J.

AU - Longo, Dan L.

AU - Sayers, Thomas J.

PY - 2015/12/15

Y1 - 2015/12/15

N2 - Cancer immunotherapy shows great promise but many patients fail to show objective responses, including in cancers that can respond well, such as melanoma and renal adenocarcinoma. The proteasome inhibitor bortezomib sensitizes solid tumors to apoptosis in response to TNF-family death ligands. Because T cells provide multiple death ligands at the tumor site, we investigated the effects of bortezomib on T-cell responses in immunotherapy models involving low-avidity antigens. Bortezomib did not affect lymphocyte or tissue-resident CD11c+ CD8+ dendritic cell counts in tumor-bearing mice, did not inhibit dendritic cell expression of costimulatory molecules, and did not decrease MHC class I/II-associated antigen presentation to cognate T cells. Rather, bortezomib activated NF-κB p65 in CD8+ T cells, stabilizing expression of T-cell receptor CD3ζ and IL2 receptor-α, while maintaining IFNγ secretion to improve FasL-mediated tumor lysis. Notably, bortezomib increased tumor cell surface expression of Fas in mice as well as human melanoma tissue from a responsive patient. In renal tumor-bearing immunodeficient Rag2-/- mice, bortezomib treatment after adoptive T-cell immunotherapy reduced lung metastases and enhanced host survival. Our findings highlight the potential of proteasome inhibitors to enhance antitumor T-cell function in the context of cancer immunotherapy.

AB - Cancer immunotherapy shows great promise but many patients fail to show objective responses, including in cancers that can respond well, such as melanoma and renal adenocarcinoma. The proteasome inhibitor bortezomib sensitizes solid tumors to apoptosis in response to TNF-family death ligands. Because T cells provide multiple death ligands at the tumor site, we investigated the effects of bortezomib on T-cell responses in immunotherapy models involving low-avidity antigens. Bortezomib did not affect lymphocyte or tissue-resident CD11c+ CD8+ dendritic cell counts in tumor-bearing mice, did not inhibit dendritic cell expression of costimulatory molecules, and did not decrease MHC class I/II-associated antigen presentation to cognate T cells. Rather, bortezomib activated NF-κB p65 in CD8+ T cells, stabilizing expression of T-cell receptor CD3ζ and IL2 receptor-α, while maintaining IFNγ secretion to improve FasL-mediated tumor lysis. Notably, bortezomib increased tumor cell surface expression of Fas in mice as well as human melanoma tissue from a responsive patient. In renal tumor-bearing immunodeficient Rag2-/- mice, bortezomib treatment after adoptive T-cell immunotherapy reduced lung metastases and enhanced host survival. Our findings highlight the potential of proteasome inhibitors to enhance antitumor T-cell function in the context of cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84955446673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955446673&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-0794

DO - 10.1158/0008-5472.CAN-15-0794

M3 - Article

C2 - 26494122

AN - SCOPUS:84955446673

VL - 75

SP - 5260

EP - 5272

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 24

ER -